Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Editorial

Biosimilar and Originator Product in Inflammatory Bowel Diseases: Mind the Gap?

Author(s): Paulo Gustavo Kotze and Silvio Danese

Volume 26 , Issue 2 , 2019

Page: [246 - 247] Pages: 2

DOI: 10.2174/092986732602190314161008

[1]
Ribeiro, P.; Fiorino, G.; Danese, S. The Experience with biosimilars of infliximab in inflammatory bowel disease. Curr. Pharm. Des., 2017, 23(44), 6759-6769.
[2]
Michetti, P. Efficacy of infliximab biosimilars in patients with Crohn’s disease. Lancet, 2017, 390(10111), 2435.
[3]
Martelli, L.; Peyrin-Biroulet, L. Efficacy, safety and immunogenicity of biosimilars in inflammatory bowel diseases: A systematic review. Curr. Med. Chem., 2019, 26(2), 270-279.
[4]
Magro, F.; Coelho, R.; Peixoto, A. Can we extrapolate data from one immune-mediated inflammatory disease to another one? Curr. Med. Chem., 2019, 26(2), 248-258.
[5]
Gulacsi, L.; Pentek, M.; Rencz, F.; Brodszky, V.; Baji, P.; Vegh, Z.; Gecse, K.B.; Danese, S.; Peyrin-Biroulet, L.; Lakatos, P.L. Biosimilars for the management of inflammatory bowel diseases: Economic considerations. Curr. Med. Chem., 2019, 26(2), 259-269.
[6]
Danese, S.; Fiorino, G. Anti-TNF biosimilars in inflammatory bowel disease: Searching the proper patient’s profile. Curr. Med. Chem., 2019, 26(2), 280-287.

© 2022 Bentham Science Publishers | Privacy Policy